Fundraising FoxNewpath Partners — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Founder)inDavid Liu(Co-founder)inAllan Reine(Chief Executive Officer)inMohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)inSvetlana Makhni(Chief Financial Officer)in
Co-investorsARCH Venture PartnersGV (Google Ventures)F-Prime CapitalOUP (Osage University Partners)Samsara BioCapitalArrive+1 more
BiotechBoston, US
Nagesh Mahanthappa, Ph.D.(Director)Luba Greenwood(Director)in
BoardAmir Nashat, Ph.D.(Treasurer and Secretary)Susan Langer(President)
Board seatThomas J. Cahill· per SEC Form D
Co-investors5AM VenturesCathay HealthPolaris Partners
Seventh Sense develops face-based biometric authentication solutions that verify identity without storing facial data, serving organizations and individuals needing secure access control, document signing, and identity verification.
AI & Machine LearningCybersecurityDeep TechDigital HealthSingapore, SG
Ashish KushwahaSam TsuiVarun Chatterji
Co-investors500 GlobalFlagship PioneeringFlagship Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.